The Pharmaceutical Journal
Vol 279 No 7470 p318
22 September 2007

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Safety of glitazones

Further evidence linking glitazones with an increased risk of heart failure has been published in JAMA.

A systematic review of longer-term rosiglitazone data suggests an increased risk of myocardial infarction and heart failure but no significant difference in cardiovascular or all-cause mortality compared with placebo (2007;298:1189).

A second study shows a reduced risk of heart attack, stroke and death for pioglitazone but an increased risk of serious heart failure (ibid, p1180).